[{"Assets_0_Q2_USD":806022000.0,"CommonStockSharesOutstanding_0_Q2_shares":50116056.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-165556000.0,"NetIncomeLoss_1_Q2_USD":-52728000.0,"NetIncomeLoss_2_Q2_USD":-22475000.0,"StockholdersEquity_0_Q2_USD":703971000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":12794000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":23471000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180803"}]